The current study was designed to evaluate whether, for patients with ER+ HER2− early breast cancer, adding the 21-gene assay to standard pathological tests would influence clinicians' and patients' treatment decisions as well as patients' decisional conflict in the United Kingdom. Here, ERBB2 is linked to breast cancer.